Journal of Cancer Research and Clinical Oncology最新文献

{"title":"Combination of oral fluoropyrimidines and EGFR-directed antibodies in frail patients with metastatic colorectal cancer: a systematic review.","authors":"Alena Annbalou Hasenburg, Sebastian Stintzing, Arndt Stahler","doi":"10.1007/s00432-026-06639-x","DOIUrl":"https://doi.org/10.1007/s00432-026-06639-x","url":null,"abstract":"<p><strong>Background: </strong>Evidence of treatment strategies in frail patients (i.e. not fit for combination therapies) with unresectable metastatic colorectal cancer (mCRC) is limited to dose-reduced doublet regimens or oral fluoropyrimidines (FP) with bevacizumab. We conducted a systematic review analyzing evidence for oral FPs with epidermal growth factor receptor (EGFR)-directed monoclonal antibodies for patients with RAS wild-type (WT) mCRC across treatment lines.</p><p><strong>Methods: </strong>We searched PubMed and Cochrane Library for phase II and phase III studies evaluating oral FPs (capecitabine, S-1 or trifluridine/tipiracil (FTD/TPI)) plus EGFR-directed monoclonal antibody (panitumumab or cetuximab) in mCRC. Outcomes included efficacy and safety.</p><p><strong>Results: </strong>Seven publications met inclusion criteria (n = 262 patients). First-line data was limited to elderly cohorts receiving capecitabine plus cetuximab or panitumumab with a median progression-free survival (PFS)/median overall survival (OS) of 7.2/17.1 months (cetuximab) and 7.5/23.7 months (panitumumab), respectively. In third-line and beyond, median PFS for the combination of FTD/TPI plus cetuximab or panitumumab ranged from 2.4 (cetuximab) to 5.8 months (panitumumab), and OS from 9.8 (cetuximab) to 14.2 months (panitumumab). S-1 plus cetuximab was associated with a median PFS of 5.5 months and OS of 13.6 months.</p><p><strong>Conclusion: </strong>While capecitabine should not be used together with anti-EGFR antibodies, FTD/TPI in combination with an EGFR-directed antibody appears feasible, shows promising activity and manageable toxicity profile in RAS WT mCRC potentially offering an alternative for frail patients; prospective trials are needed.</p>","PeriodicalId":15118,"journal":{"name":"Journal of Cancer Research and Clinical Oncology","volume":"152 10","pages":""},"PeriodicalIF":3.3,"publicationDate":"2026-10-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149227840","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Management of extravasations of enfortumab vedotin and pembrolizumab: a case report and mini review of the current literature.","authors":"Hendrik Dinkel, Konstantin E Seifert, Martin Bögemann, Andres J Schrader, Katrin Schlack","doi":"10.1007/s00432-026-06646-y","DOIUrl":"10.1007/s00432-026-06646-y","url":null,"abstract":"<p><p>Following the EV-302/KEYNOTE-A39 study, the combination therapy of enfortumab vedotin and pembrolizumab (EV-P) has been established as a new first-line treatment for metastatic urothelial carcinoma. With increasing use, the documentation and publication of unexpected side effects and complications are essential to systematize procedures. We report on a 56-year-old patient who experienced an extravasation of EV-P during the first cycle due to dislocation of the port catheter from the cephalic vein. Extensive subcutaneous necrosis of the infraclavicular region required surgical debridement and application of a vacuum-assisted closure system, followed by secondary wound healing. The wound healed with a residual scar but no functional impairment or persistent pain. The therapy was resumed via a peripheral venous catheter, and the patient achieved a deep partial response. To our knowledge, this represents the first reported case of central venous EV-P extravasation (CTCAE grade 3) requiring surgical therapy. Because of its cytotoxic payload, EV in particular may pose a high risk of local complications in the context of extravasations.</p>","PeriodicalId":15118,"journal":{"name":"Journal of Cancer Research and Clinical Oncology","volume":"152 10","pages":""},"PeriodicalIF":3.3,"publicationDate":"2026-10-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13675447/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149206834","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"CT-to-surgery interval and occult nodal metastasis in cN0 oral squamous cell carcinoma.","authors":"Jannik Ketschau, Jonathan Mohr, Alex Grabenhorst, Hannes Singer, Helena Richter, Nils Krautkremer, Minli Niu, Katharina Pippich, Herbert Stimmer, Markus Graf, Klaus-Dietrich Wolff, Lucas M Ritschl","doi":"10.1007/s00432-026-06642-2","DOIUrl":"10.1007/s00432-026-06642-2","url":null,"abstract":"<p><strong>Background: </strong>CT-based staging of the clinically node-negative (cN0) neck in oral squamous cell carcinoma (OSCC) has limited sensitivity, and occult nodal metastasis remains common. Whether the CT-to-surgery interval influences pathological nodal outcome is unclear.</p><p><strong>Methods: </strong>This retrospective study included 329 patients with primary cN0 OSCC undergoing CT staging and neck dissection (2011-2024). Associations with lymph node positivity, lymph node count, and extranodal extension (ENE) were assessed using logistic and negative binomial regression, with sensitivity analyses (quartiles, exclusion of extreme intervals, lymph node yield adjustment).</p><p><strong>Results: </strong>Median CT-to-surgery interval was 9.0 days (IQR 5.0-15.0), and 53 patients (16.1%) had lymph node metastasis. The interval was associated with lymph node positivity in univariable analysis (OR 1.031, p = 0.035), but not after adjustment for age and smoking (OR 1.027, p = 0.065); lymph node count showed a similar non-significant association (IRR 1.027, p = 0.068). The association with nodal positivity was not robust across interval quartiles (p = 0.969), after excluding intervals >30 days (OR 0.995, p = 0.824), or after adjustment for lymph node yield (OR 1.015, p = 0.334). However, patients with intervals >30 days (n = 13) had higher nodal positivity than those with shorter intervals (53.8% vs. 14.6%). The interval was not associated with ENE (p = 0.740), and tumor localization was not associated with nodal positivity (p = 0.175).</p><p><strong>Conclusion: </strong>An initially significant, unadjusted association was not robust to sensitivity testing and was confined to a small subgroup with substantially prolonged intervals. This offers some reassurance that the CT-to-surgery interval is not strongly associated with occult nodal metastasis in cN0 OSCC, while substantially delayed surgery warrants further investigation.</p>","PeriodicalId":15118,"journal":{"name":"Journal of Cancer Research and Clinical Oncology","volume":"152 10","pages":""},"PeriodicalIF":3.3,"publicationDate":"2026-10-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13675429/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149206836","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Evaluation of novel targeted small-molecule therapeutics in desmoplastic small round cell tumor (DSRCT) cells.","authors":"Anne Hahn, Julia Hentschel, Shifa Saleem, Sabine Becker, Thomas Liehr, Andreas Schober, Oliver H Krämer, Jürgen Sonnemann, Christian Marx","doi":"10.1007/s00432-026-06630-6","DOIUrl":"https://doi.org/10.1007/s00432-026-06630-6","url":null,"abstract":"<p><strong>Purpose: </strong>Desmoplastic small round cell tumor (DSRCT) is an aggressive sarcoma associated with an extremely poor prognosis. This study evaluates the therapeutic potential of targeted, non-DNA-damaging small-molecule inhibitors in an in vitro DSRCT model.</p><p><strong>Methods: </strong>We characterized the genomic architecture of the JN-DSRCT-1 cell line using fluorescence in situ hybridization (FISH) and sequencing of the tumor suppressor TP53. In silico analysis was performed to identify shared vulnerabilities between DSRCT and Ewing sarcoma (ES). Using flow cytometry (assessing cell death, mitochondrial membrane potential loss, caspase-3 activity, and cell cycle distribution) and quantitative real-time PCR (qPCR), we systematically evaluated a small-molecule screening panel. The panel targeted chromatin acetylation (entinostat, vorinostat, tenovin-1), p53 pathway activity (RETRA, nutlin-3, RITA), receptor tyrosine kinases (imatinib), and transcription factor DNA-binding dynamics (mithramycin).</p><p><strong>Results: </strong>JN-DSRCT-1 cells exhibited complex aneuploidy, and we confirmed the presence of the pathognomonic balanced EWSR1::WT1 translocation. Histone deacetylase inhibitors (entinostat, vorinostat) and nutlin-3 (an MDM2 antagonist) triggered robust intrinsic apoptosis and upregulated p53 target genes (p21, PUMA, and NOXA). Mithramycin demonstrated high cytotoxicity, whereas imatinib was ineffective. Pan-caspase inhibition using z-VAD-FMK rescued cells from entinostat-, vorinostat-, nutlin-3-, and mithramycin-induced death, but failed to protect against tenovin-1, RITA, or RETRA, indicating the activation of caspase-independent cell death pathways.</p><p><strong>Conclusion: </strong>DSRCT cells display high sensitivity to histone deacetylase inhibition, p53 pathway activation, and mithramycin. Among these, histone deacetylase inhibition alone or in combination with other small molecule drugs represents a particularly promising strategy for overcoming DSRCT cell survival.</p>","PeriodicalId":15118,"journal":{"name":"Journal of Cancer Research and Clinical Oncology","volume":"152 10","pages":""},"PeriodicalIF":3.3,"publicationDate":"2026-10-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13634027/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149110118","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Longer-term response to SARS-CoV-2 vaccination after allogeneic blood stem cell transplantation.","authors":"Carl C Crodel, Laura Gork, Wibke Göpel, Paul Linke, Konrad Sinn, Jenny Miethke, Andreas Hochhaus, Inken Hilgendorf","doi":"10.1007/s00432-026-06632-4","DOIUrl":"https://doi.org/10.1007/s00432-026-06632-4","url":null,"abstract":"<p><strong>Introduction: </strong>Recipients of allogeneic haematopoietic stem cell transplantation (alloHSCT) are at increased risk of COVID-19 and lower vaccine immunogenicity. This study assessed vaccine immunogenicity and safety in these patients.</p><p><strong>Methods: </strong>We analyzed the serological response after the 2nd and 3rd SARS-CoV-2 vaccination as well as potential factors influencing this response. Data were obtained from internal hospital records. In addition, a questionnaire was used to evaluate the vaccination status, vaccination side effects and the course of expired COVID-19 disease.</p><p><strong>Results: </strong>In total, 114 patients (median age 62, range 27 - 70) were enrolled between July and September 2022, with 55 females (48.2%). One year later a follow up was conducted. Most patients (89.4%) were vaccinated at least twice, 66.7% received three vaccinations, and 10.5% refused the vaccination. The mRNA vaccines were predominantly used. Most patients responded and reached SARS-CoV-2 spike IgG titers after the 2nd (81.8%) or 3rd (96.1%) vaccination. Patients vaccinated within 24 months of alloHSCT had significantly lower anti-spike IgG levels than those vaccinated later (p=0.017). Common side effects included arm pain (34%), swelling (14%), and limb pain (17%).</p><p><strong>Conclusion: </strong>Vaccination was feasible and well-tolerated in alloHSCT recipients. Timing of vaccination influenced immune response, with a stronger response after the 3rd dose compared to the initial series.</p>","PeriodicalId":15118,"journal":{"name":"Journal of Cancer Research and Clinical Oncology","volume":"152 10","pages":""},"PeriodicalIF":3.3,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13634024/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149110130","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comment on \"Treatment of retroperitoneal sarcoma in Germany between 2000 and 2022: a retrospective analysis from the German Cancer Registry Group\".","authors":"R Saravanan, Paramanantham Madhavan, R Sivayogana, K Anusha","doi":"10.1007/s00432-026-06591-w","DOIUrl":"https://doi.org/10.1007/s00432-026-06591-w","url":null,"abstract":"<p><p>The nationwide registry analysis by Beck et al. provides valuable insights into treatment patterns for retroperitoneal sarcoma in Germany over two decades, highlighting increasing use of multivisceral resection and improved survival analyses. While the study establishes an important framework for evaluating rare cancers using registry data, several methodological issues may influence the interpretation of the reported temporal trends and clinical conclusions. First, the observed increase in multivisceral resection may partly reflect progressive improvements in registry documentation and procedure coding rather than a true change in surgical practice. Second, substantial missing data for tumor grade and metastatic status raise concerns regarding potential selection bias in survival analyses performed on complete cases without sensitivity analyses. Addressing documentation completeness and the impact of missing data would strengthen confidence in the reported findings and improve the applicability of registry-based evidence for clinical decision-making and future rare cancer research.</p>","PeriodicalId":15118,"journal":{"name":"Journal of Cancer Research and Clinical Oncology","volume":"152 10","pages":""},"PeriodicalIF":3.3,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13631140/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149110137","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comparative Cost and Utilization Analysis of CAR-T Therapy and Autologous Stem Cell Transplantation for Diffuse Large B-Cell Lymphoma in Germany: Insights from Statutory Health Insurance Billing and Nationwide Inpatient Data.","authors":"Ann-Cathrine Froitzheim, Melina Sophie Kurte, Katja Gehrke, Sebastian Lempfert, Katja Hesse, Florian Kron","doi":"10.1007/s00432-026-06628-0","DOIUrl":"https://doi.org/10.1007/s00432-026-06628-0","url":null,"abstract":"<p><strong>Purpose: </strong>Chimeric Antigen Receptor (CAR) T-cell therapy has transformed the treatment of diffuse large B-cell lymphoma (DLBCL) but carries higher drug acquisition costs than autologous stem cell transplantation (autoSCT), while administration and follow-up costs remain underrepresented in economic evaluations and reimbursement decision-making. This study compares administration-related and subsequent treatment costs of CAR-T and autoSCT for DLBCL from the German statutory health insurance (SHI) perspective.</p><p><strong>Methods: </strong>A two-step analysis based on two German databases was performed. In step 1, SHI billing data (representing 5 million insured individuals, ≙ 8% of SHI) from 2020-2022 were analyzed longitudinally. Costs were divided into initial regime (IR) (all services except CAR-T drug acquisition) and a following regime (FR). In step 2, a cross-sectional analysis of all German inpatient cases from 2020-2023 (17 million cases/year) assessed inpatient costs.</p><p><strong>Results: </strong>Step 1 included 12 CAR-T and 59 autoSCT patients. Median IR costs per patient were €61,703 (CAR-T) versus €55,802 (autoSCT), while FR costs were lower for CAR-T (€44,832 versus €69,453). Most frequently reported adverse events (any grade) for CAR-T versus autoSCT were: B-cell aplasia/neutropenia (77% versus 64%), thrombocytopenia (38% versus 64%). Step 2 included 1,229 CAR-T and 2,239 autoSCT inpatient cases (2020-2023). Average LOS was comparable (27.3 versus 27.8 days), and average inpatient costs were lower for CAR-T (€13,991 versus €29,432).</p><p><strong>Conclusion: </strong>Although associated with higher IR costs, CAR-T therapy in DLBCL demonstrated lower inpatient and FR costs compared to autoSCT. This analysis focused on administration and follow-up costs, excluding drug acquisition costs, characterizing the economic burden beyond drug pricing.</p>","PeriodicalId":15118,"journal":{"name":"Journal of Cancer Research and Clinical Oncology","volume":"152 10","pages":""},"PeriodicalIF":3.3,"publicationDate":"2026-09-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13631127/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149110204","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comment on \"Theranostic lipid nanocarriers for precision diagnosis and targeted therapy in pancreatic ductal adenocarcinoma\".","authors":"Khayrullina Aliya Khakimovna, Samadov Bakhodirjon, J Joseph Armstrong","doi":"10.1007/s00432-026-06618-2","DOIUrl":"10.1007/s00432-026-06618-2","url":null,"abstract":"<p><p>This letter comments on a recent review of theranostic lipid nanocarriers for pancreatic ductal adenocarcinoma, identifying three areas of concern in the evidence base. First, the 211-item reference list contains multiple duplicated citations listed under separate numbers with identical content (for example, refs. 6/8, 9/21, 55/89, 106/117, 132/143), a recurring pattern suggesting that the bibliography was not fully verified before submission. Second, Table 6 cites reference markers \"[639]\" and \"[640]\" for the NanoSMART and NBTXR3 trials, numbers that exceed the 211-entry reference list and appear to be residual artifacts from a source document with a different numbering scheme. Third, the review reports that NC-6004 (a micellar cisplatin formulation) has completed a phase III trial in combination with gemcitabine but omits the trial's outcome, despite the review's broader argument for the translational viability of lipid- and micelle-based nanocarriers and its extended discussion of nab-paclitaxel as a successful precedent. Reporting this outcome, favorable or not, alongside existing precedents, would allow readers to weigh the review's central claim against the complete record of late-stage clinical testing. While the review offers a valuable catalogue of nanocarrier platforms and regulatory precedents, these issues warrant correction before the citation base is treated as fully reliable.</p>","PeriodicalId":15118,"journal":{"name":"Journal of Cancer Research and Clinical Oncology","volume":"152 9","pages":""},"PeriodicalIF":3.3,"publicationDate":"2026-09-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13615218/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149061317","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Sleep quality and disturbances in adolescents and young adults with cancer compared to a healthy comparison group: results of the AYA-LE study.","authors":"Carolin Wieland, Michael Friedrich, Annekathrin Sender, Katja Leuteritz, Hannah Brock, Kristina Geue, Anja Mehnert-Theuerkauf, Diana Richter","doi":"10.1007/s00432-026-06627-1","DOIUrl":"10.1007/s00432-026-06627-1","url":null,"abstract":"<p><strong>Purpose: </strong>Adolescents and young adults (AYAs) with cancer often exhibit riskier health behaviors, including poorer sleep patterns, compared to older individuals. Research on the relationship between cancer and sleep quality in AYA patients has yielded inconsistent results. This study investigates sleep quality in AYA patients compared to a healthy comparison group and examines associated sociodemographic, clinical, and psychosocial variables as well as physical activity.</p><p><strong>Methods: </strong>The prospective observational study included 407 AYA patients aged 18-39 years at diagnosis and 372 healthy participants aged 18-45 years, with data collected from May-September 2019. Sleep quality was assessed using the Pittsburgh Sleep Quality Index (PSQI). Validated questionnaires measured self-efficacy, social support, anxiety, depression, quality of life, lack of energy, and physical activity. Multiple regression analyses were employed to explore the variables associated with sleep quality.</p><p><strong>Results: </strong>The mean age of the AYA patients was 34.8 years (75.2% women) and 32.3 years of the healthy participants (61.8% women). AYA patients demonstrated significantly poorer subjective sleep quality (d=0.31), lower sleep efficiency (d=0.15), more frequent sleep disturbances (d=0.23), greater use of sleep medication (d=0.25), and higher daytime dysfunction (d=0.29). Anxiety, depression (HADS), quality of life (EORTC), and unmet needs for support through lack of energy (SCNS) were significantly associated with PSQI (adjusted R²=0.35).</p><p><strong>Conclusion: </strong>These findings underscore the relevance of sleep disturbances in AYA patients and support greater attention to sleep disturbances in survivorship care. Routine assessment of sleep quality may help identify AYA patients who could benefit from further evaluation and appropriate support.</p>","PeriodicalId":15118,"journal":{"name":"Journal of Cancer Research and Clinical Oncology","volume":"152 9","pages":""},"PeriodicalIF":3.3,"publicationDate":"2026-09-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13601403/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149030320","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Correction: Should lymphadenectomy be recommended in radical surgery of intrahepatic cholangiocarcinoma patients? A retrospective study.","authors":"Ruoyu Zhang, Dayong Cao, Min Yang, Jiajun Zhang, Feng Ye, Ning Huang, Mei Liu, Bo Chen, Liming Wang","doi":"10.1007/s00432-026-06606-6","DOIUrl":"10.1007/s00432-026-06606-6","url":null,"abstract":"","PeriodicalId":15118,"journal":{"name":"Journal of Cancer Research and Clinical Oncology","volume":"152 9","pages":""},"PeriodicalIF":3.3,"publicationDate":"2026-09-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13598047/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149024890","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}